<SEC-DOCUMENT>0001193125-24-237192.txt : 20241015
<SEC-HEADER>0001193125-24-237192.hdr.sgml : 20241015
<ACCEPTANCE-DATETIME>20241015070313
ACCESSION NUMBER:		0001193125-24-237192
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20241015
DATE AS OF CHANGE:		20241015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276774
		FILM NUMBER:		241369223

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d726235d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR>Registration No. 333-276774 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
February&nbsp;5, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>4,755,556 American Depositary Shares representing 47,555,560 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g726235g1015031214016.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February&nbsp;5, 2024 (the
&#147;Prospectus&#148;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-276774),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on October&nbsp;15, 2024 (the &#147;October 15, 2024 Form <FONT STYLE="white-space:nowrap">6-K&#148;).</FONT> Accordingly, we have
attached the October&nbsp;15, 2024 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates and
supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in
conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#147;Nasdaq&#148;) under the symbol &#147;KZIA.&#148; On October&nbsp;14, 2024, the last reported sale
price of the ADSs on Nasdaq was $0.4026 per ADS. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities
involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page 9 of the Prospectus and the &#147;Risk Factors&#148; in &#147;Item 3. Key Information&#151;D. Risk Factors&#148; of our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus supplement is October&nbsp;15, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (the &#147;Company&#148;) plans to change the ratio of its American Depositary Shares (&#147;ADSs&#148;)
to Ordinary Shares from one (1)&nbsp;ADS representing ten (10)&nbsp;Ordinary Shares to one (1)&nbsp;ADS representing one hundred (100)&nbsp;Ordinary Shares (the &#147;ADS Ratio Change&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There will be no change to our underlying Ordinary Shares, and no Ordinary Shares will be issued or cancelled in connection with the ADS Ratio
Change. The effect of the ratio change on the ADS trading price on the Nasdaq Capital Market is expected to take place at the opening of business on October&nbsp;28, 2024. Following the ADS Ratio Change, our ADSs will continue to be traded on the
Nasdaq Capital Market under the ticker symbol &#147;KZIA.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional new ADSs will be issued in connection with the ADS Ratio
Change. Instead, fractional entitlements to the new ADSs will be aggregated and sold by the depositary bank, and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes, and expenses) will be
distributed to the applicable ADS holders by the depositary bank. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the ADS Ratio Change, the ADS price is expected to
increase proportionally, although the Company can give no assurance that the ADS price after the ADS Ratio Change will be equal to or greater than ten times the ADS price before the ADS Ratio Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Board of Directors approved the ADS Ratio Change with the objective of regaining compliance with the minimum bid price of
$1.00 per share as outlined in the Nasdaq Listing Rules. The Company has until November 18, 2024 to regain compliance. The Company can give no assurance that this event will result in the company meeting Nasdaq&#146;s minimum bid price requirement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein into the Company&#146;s registration statements on Form <FONT
STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-276091</FONT> and <FONT STYLE="white-space:nowrap">333-281937).</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain
statements in this Report on Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">6-K-</FONT></FONT> that are forward-looking and not statements of historical fact are forward-looking statements, which can generally be identified
as such by the use of words such as &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any statement describing Kazia&#146;s future plans, strategies,
intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forwardlooking statements, including, but not limited to, statements regarding: the timing for results and data related to
Kazia&#146;s clinical and preclinical trials, Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801, the potential benefits of paxalisib as an investigational PI3K/mTOR inhibitor, timing for any regulatory
submissions or discussions with regulatory agencies, the potential market opportunity for paxalisib, and the ADS Ratio Change. Such statements are based on Kazia&#146;s current expectations and projections about future events and future trends
affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and
preclinical trials and product development, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia&#146;s Annual Report, filed on form <FONT
STYLE="white-space:nowrap">20-F</FONT> with the United States Securities and Exchange Commission (the &#147;SEC&#148;), and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether
as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this report. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited </B>(Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 15&nbsp;October 2024</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g726235g1015031214016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g726235g1015031214016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] -4# 2(  A$! Q$!_\0
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M'^&0=/S'%;35T9Q=F>Z#I43JA)+JIP,Y([5(.E<9\1_$7]A>&Y$B?%W=YBB
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..B@8M%)10 M%)10!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
